These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 26190064)

  • 1. A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities.
    Sun M; Trinh QD
    BJU Int; 2016 Apr; 117(4):551-2. PubMed ID: 26190064
    [No Abstract]   [Full Text] [Related]  

  • 2. The dynamics of death in prostate cancer.
    Vollmer RT
    Am J Clin Pathol; 2012 Jun; 137(6):957-62. PubMed ID: 22586055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
    Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
    J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations and biases of the Surveillance, Epidemiology, and End Results database.
    Park HS; Lloyd S; Decker RH; Wilson LD; Yu JB
    Curr Probl Cancer; 2012; 36(4):216-24. PubMed ID: 22481009
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
    Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
    J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of Gleason scores in metastatic prostate cancer.
    Rusthoven CG; Carlson JA; Waxweiler TV; Yeh N; Raben D; Flaig TW; Kavanagh BD
    Urol Oncol; 2014 Jul; 32(5):707-13. PubMed ID: 24629494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.
    Scosyrev E; Wu G; Mohile S; Messing EM
    Cancer; 2012 Dec; 118(23):5768-76. PubMed ID: 22847578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing Bias in Oncology Research: The End of the Radiation Variable in the Surveillance, Epidemiology, and End Results (SEER) Program.
    Walker GV; Grant SR; Jagsi R; Smith BD
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):302-303. PubMed ID: 28871979
    [No Abstract]   [Full Text] [Related]  

  • 9. Urology meeting highlights prostate, bladder cancers.
    Fillon M
    J Natl Cancer Inst; 2012 Sep; 104(18):1348-9. PubMed ID: 22984200
    [No Abstract]   [Full Text] [Related]  

  • 10. A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.
    Terakedis BE; Rossi PJ; Liauw SL; Johnstone PA; Jani AB
    Am J Clin Oncol; 2010 Dec; 33(6):619-23. PubMed ID: 20051808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical relapse in prostate cancer: is PSA promoting stress and anxiety?
    Slovin S
    MedGenMed; 2002 Aug; 4(3):11. PubMed ID: 12466754
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database.
    Shukla ME; Yu C; Reddy CA; Stephans KL; Klein EA; Abdel-Wahab M; Ciezki J; Tendulkar RD
    Clin Genitourin Cancer; 2015 Feb; 13(1):17-21. PubMed ID: 25571871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.
    Stephenson RA; Smart CR; Mineau GP; James BC; Janerich DT; Dibble RL
    Cancer; 1996 Apr; 77(7):1342-8. PubMed ID: 8608513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based or evidence-biased medicine?
    Anand AC
    Natl Med J India; 2006; 19(2):100-3. PubMed ID: 16756200
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer screening: is it possible to explain diametrically opposed views?
    Richardson A
    N Z Med J; 2005 Feb; 118(1209):U1289. PubMed ID: 15711622
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer: A challenge for screening.
    Donnell RF
    Surg Oncol Clin N Am; 1999 Oct; 8(4):693-702, vii. PubMed ID: 10452935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In depth analysis of 2 studies of prostate cancer screening--what makes sense?].
    Recker F
    Praxis (Bern 1994); 2010 Feb; 99(3):183-5. PubMed ID: 20127638
    [No Abstract]   [Full Text] [Related]  

  • 18. Prediction models, nomograms, and staging validation with the Surveillance, Epidemiology, and End Results database: using Surveillance, Epidemiology and End Results (SEER) program to create prediction models.
    Lloyd S; Park HS; Wilson LD; Decker RH; Yu JB
    Curr Probl Cancer; 2012; 36(4):200-7. PubMed ID: 22481008
    [No Abstract]   [Full Text] [Related]  

  • 19. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
    Muralidhar V; Chen MH; Reznor G; Moran BJ; Braccioforte MH; Beard CJ; Feng FY; Hoffman KE; Choueiri TK; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):828-35. PubMed ID: 26530751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening: Diagnostic dilemma.
    Sohn E
    Nature; 2015 Dec; 528(7582):S120-2. PubMed ID: 26672781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.